Ad
related to: astrazeneca stock- Trade
Buy, sell, track the market.
Discover our investment products.
- Ranked #1 in Research
Kiplinger's Best Online Brokers
Annual Review from August 31, 2023
- Open an Account
Choose The Account That Works
Best For You, and Start Investing
- Learn How To Trade
We can help you invest with speed
& accuracy at every step of a trade
- Trade
Search results
First Trust Advisors LP Raises Stock Position in AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 20 hours agoThe institutional investor owned 1,390,959 shares of the company’s stock after buying an additional 95,652 shares during the period. First Trust Advisors LP’s holdings in ...
AstraZeneca Buy rating, stock target reiterated on consistent presence By Investing.com
Investing.com· 2 days agoOn Wednesday, Citi reaffirmed its Buy rating on AstraZeneca (NASDAQ:AZN) shares with a steady price...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks· 4 days agoFree Report) closed the most recent trading day at $78.99, moving +1.24% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.11%. Coming into today, shares of ...
AstraZeneca completes acquisition of biopharma company Fusion Pharma
dpa international via Yahoo Finance· 2 days agoBritish pharmaceutical company AstraZeneca on Wednesday announced the completion of the acquisition...
3 No-Brainer Stocks to Buy in June
Motley Fool via Yahoo Finance· 5 days agoTrading at 18 times its expected future earnings, the stock's valuation is attractive when compared to the average healthcare stock, which trades at a...
Deutsche Bank maintains 'Hold' on AstraZeneca post ASCO conference By Investing.com
Investing.com· 2 days agoOn Monday, Deutsche Bank reiterated a Hold rating and a price target of GBP110.00 on stock of ...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 7 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
Forbes· 1 day agoThe conference was a big one for Summit Therapeutics, which saw its stock price more than double...
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
InvestorPlace· 17 hours agoThis however holds true for high-quality blue-chip and growth stocks. On the other hand, in an...
Cramer's Lighting Round: 'You've got a winner' with Astra Zeneca
CNBC· 6 days ago"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to...
